<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005116A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005116</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13807378</doc-number><date>20110628</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>05</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>05</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>514 186</main-classification></classification-national><invention-title id="d0e43">KELOID TREATMENT</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61359053</doc-number><date>20100628</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Obayan</last-name><first-name>Adebola O.E.</first-name><address><city>Saskatchewan</city><country>CA</country></address></addressbook><residence><country>CA</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only"><addressbook><last-name>Singh</last-name><first-name>Sanjeev</first-name><address><city>Saskatchewan</city><country>CA</country></address></addressbook><residence><country>CA</country></residence></us-applicant><us-applicant sequence="02" app-type="applicant" designation="us-only"><addressbook><last-name>Yuzdepski</last-name><first-name>Brenda Collen Joyce</first-name><address><city>Saskatchewan</city><country>CA</country></address></addressbook><residence><country>CA</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Obayan</last-name><first-name>Adebola O.E.</first-name><address><city>Saskatchewan</city><country>CA</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Singh</last-name><first-name>Sanjeev</first-name><address><city>Saskatchewan</city><country>CA</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Yuzdepski</last-name><first-name>Brenda Collen Joyce</first-name><address><city>Saskatchewan</city><country>CA</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>ADE THERAPEUTICS INC.</orgname><role>03</role><address><city>Saskatchewan</city><country>CA</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/CA11/50396</doc-number><kind>00</kind><date>20110628</date></document-id><us-371c124-date><date>20130911</date></us-371c124-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Due to a long-standing interest in scar reduction, alanyl-glutamine was tested for ability to treat keloid scars, despite the difficulties associated with delivering compounds above a certain size threshold across the skin barrier to the dermis where new skin is formed. Surprisingly, it was found that a dermal application formulation of alanyl-glutamine was effective in reducing the severity and/or preventing the formation of keloid scars.</p></abstract></us-patent-application>